Low PPP2R2A expression promotes sensitivity to CHK1 inhibition in high-grade serous ovarian cancer
2024

Low PPP2R2A Expression and CHK1 Inhibition in Ovarian Cancer

publication Evidence: high

Author Information

Author(s): Qiu Zhaojun, Sigh Deepika, Liu Yujie, Prasad Chandra B., Bean Nichalos, Yan Chunhong, Li Zaibo, Zhang Xiaoli, Narla Goutham, DiFeo Analisa, Wang Qi-En, Zhang Junran

Primary Institution: The Ohio State University

Hypothesis

Does PPP2R2A deficiency enhance the sensitivity of high-grade serous ovarian cancer (HGSOC) to CHK1 inhibition?

Conclusion

PPP2R2A deficiency increases sensitivity to CHK1 inhibitors in HGSOC, suggesting it as a potential biomarker and therapeutic target.

Supporting Evidence

  • PPP2R2A deficiency is linked to increased sensitivity to CHK1 inhibitors.
  • Low expression of PPP2R2A correlates with poor prognosis in ovarian cancer.
  • CHK1 inhibition shows promise in treating HGSOC with PPP2R2A deficiency.

Takeaway

If a certain protein is low in ovarian cancer cells, those cells are more likely to be hurt by a specific cancer treatment.

Methodology

The study involved treating HGSOC cells with a CHK1 inhibitor and assessing cell growth through in vitro and in vivo assays.

Digital Object Identifier (DOI)

10.7150/thno.96879

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication